The National Institute for Health and Care Excellence

NICE’s backing of the prostate cancer drug abiraterone could help thousands and save the NHS millions

We estimate the NHS could potentially save £millions annually by greater use of the generic version of abiraterone rather than using enzalutamide and apalutamide, the other treatments we recommend at ...
The National Institute for Health and Care Excellence

Focusing on what matters most to the NHS

The prioritisation board, made up of senior members of NICE, drives our decision-making and maintains oversight of our guidance portfolio. It ensures the topics we select reflect national priorities ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal) TA1104 22 October 2025 22 October 2025 Clascoterone for treating ...
National Institute for Health and Care Excellence

Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) British National Formulary for Children (BNFC) Life sciences Library and knowledge services What ...
National Institute for Health and Care Excellence

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal ...
National Institute for Health and Care Excellence

COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community

This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
National Institute for Health and Care Excellence

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies. Next review: More ...
National Institute for Health and Care Excellence

Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) British National Formulary for Children (BNFC) Life sciences Library and knowledge services What ...
National Institute for Health and Care Excellence

Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, ARCHITECT STAT High Sensitive Troponin-I and AccuTnI+3 ...

Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, ARCHITECT STAT High Sensitive Troponin-I and AccuTnI+3 assays) Diagnostics ...
National Institute for Health and Care Excellence

Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults

This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z‑drugs and antidepressants in primary and secondary care. It does not ...
National Institute for Health and Care Excellence

Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides

1.2 This recommendation is not intended to affect treatment with icosapent ethyl that was started in the NHS before this guidance was published. People having treatment outside this recommendation may ...